- Eisai and Biogen posted promising data for BAN2401 that lifted its stock and had the pharma trade publications talking breakthrough.
- But there is a lot of controversy swirling around the study.
- It seems that Biogen may have moved the goal posts to gain more favorable data endpoints.
- It’s not about patients, it’s about the stock price and getting investors on board.
KEY TAKEAWAY: Spending $40 million on a DTC campaign to increase awareness of a drug that people are demolishing on social media is a waste of money. Surely DTC marketers can do better than this.
KEY SUMMARY: I received a lot of comments on my post about Biogen’s layoffs, but I didn’t expect them to be so one-sided. It seems that in fact Biogen does have an issue and it is centered around their CEO who has a history of laying off people while taking an eight figure salary.
KEY TAKEAWAY: While investors seem to buy or sell on tidbits of news about new drugs ultimately it’s patients who win or lose when new drugs make it through the stringent development and approval process. The dedication of the employees at Biogen Idec are going to have to put in a lot of hours to ensure that the promise of the pipeline is fulfilled.